Terms: = Leukemia AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
82 results:
1. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
[TBL] [Abstract] [Full Text] [Related]
2. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L; Grieb N; Born P; Weiss R; Seiffert S; Boldt A; Fricke S; Franz P; Heyn S; Kubasch AS; Baber R; Weidner H; Wang SY; Bach E; Hoffmann S; Ussmann J; Kirchberg J; Hell S; Schwind S; Metzeler KH; Herling M; Jentzsch M; Franke GN; Sack U; Reiche K; Köhl U; Platzbecker U; Vucinic V; Merz M
Leukemia; 2024 Feb; 38(2):372-382. PubMed ID: 38184754
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract] [Full Text] [Related]
4. [Novel CD19-KIRS2/Dap12-BB CAR-T treatment for 3 Patients with Relapsed and Refractory B-Cell Tumors].
Ji SW; Hua T; Wang JJ; Shao LY; Chen ZH; Liu JY; Cheng H; Chen W; Sun C; Wang X; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1860-1865. PubMed ID: 38071073
[TBL] [Abstract] [Full Text] [Related]
5. Bispecific CS1-bcma CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract] [Full Text] [Related]
6. bcma-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract] [Full Text] [Related]
7. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior bcma-targeted therapy.
Ferreri CJ; Hildebrandt MAT; Hashmi H; Shune LO; McGuirk JP; Sborov DW; Wagner CB; Kocoglu MH; Rapoport A; Atrash S; Voorhees PM; Khouri J; Dima D; Afrough A; Kaur G; Anderson LD; Simmons G; Davis JA; Kalariya N; Peres LC; Lin Y; Janakiram M; Nadeem O; Alsina M; Locke FL; Sidana S; Hansen DK; Patel KK; Castaneda Puglianini OA
Blood Cancer J; 2023 Aug; 13(1):117. PubMed ID: 37558706
[TBL] [Abstract] [Full Text] [Related]
8. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia.
Feng Y; Chen T; Zhang Y; Yao H; Wang P; Wang L; Cassady K; Zou Z; Liu Y; Zhao L; Gao L; Zhang X; Kong P
Front Immunol; 2023; 14():1182251. PubMed ID: 37435080
[TBL] [Abstract] [Full Text] [Related]
9. γ-Secretase inhibitor in combination with bcma chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract] [Full Text] [Related]
10. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract] [Full Text] [Related]
11. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract] [Full Text] [Related]
12. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract] [Full Text] [Related]
13. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
Terpos E; Musto P; Engelhardt M; Delforge M; Cook G; Gay F; van de Donk NWCJ; Ntanasis-Stathopoulos I; Vangsted AJ; Driessen C; Schjesvold F; Cerchione C; Zweegman S; Hajek R; Moreau P; Einsele H; San-Miguel J; Boccadoro M; Dimopoulos MA; Sonneveld P; Ludwig H
Leukemia; 2023 Jun; 37(6):1175-1185. PubMed ID: 37142661
[TBL] [Abstract] [Full Text] [Related]
14. bcma CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract] [Full Text] [Related]
15. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract] [Full Text] [Related]
16. Redirecting T-cell Activity with Anti-bcma/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic leukemia and Other B-cell Lymphomas.
Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
[TBL] [Abstract] [Full Text] [Related]
17. Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases.
Wang D; He L; Li C; Xu M; Yu Q; Almeida VDF; Que Y; Xu Y; Xiao Y; Li C
BMC Infect Dis; 2023 Feb; 23(1):109. PubMed ID: 36814216
[TBL] [Abstract] [Full Text] [Related]
18. Th17.1 cell driven sarcoidosis-like inflammation after anti-bcma CAR T cells in multiple myeloma.
Leipold AM; Werner RA; Düll J; Jung P; John M; Stanojkovska E; Zhou X; Hornburger H; Ruckdeschel A; Dietrich O; Imdahl F; Krammer T; Knop S; Rosenwald A; Buck A; Sander LE; Einsele H; Kortüm KM; Saliba AE; Rasche L
Leukemia; 2023 Mar; 37(3):650-658. PubMed ID: 36720972
[TBL] [Abstract] [Full Text] [Related]
19. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract] [Full Text] [Related]
20. Anti-bcma/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Garfall AL; Cohen AD; Susanibar-Adaniya SP; Hwang WT; Vogl DT; Waxman AJ; Lacey SF; Gonzalez VE; Fraietta JA; Gupta M; Kulikovskaya I; Tian L; Chen F; Koterba N; Bartoszek RL; Patchin M; Xu R; Plesa G; Siegel DL; Brennan A; Nelson AM; Ferthio R; Cosey A; Shea KM; Leskowitz R; Four M; Wilson WV; Miao F; Lancaster E; Carreno BM; Linette GP; Hexner EO; Young RM; Bu D; Mansfield KG; Brogdon JL; June CH; Milone MC; Stadtmauer EA
Blood Cancer Discov; 2023 Mar; 4(2):118-133. PubMed ID: 36413381
[TBL] [Abstract] [Full Text] [Related]
[Next]
